The nuclear receptor peroxisome proliferator-activated receptor g (PPARg) is a key transcriptional regulator of both lipid metabolism and inflammation. The importance of PPARg is accentuated by the widespread use of synthetic PPARg agonists, thiazolidinediones (such as rosiglitazone), as drugs for insulin resistance and type II diabetes. Fractalkine (FKN) and FKN receptor (FR) play an important role in the immune responses by regulating leukocyte migration and adhesion to inflamed peripheral tissues. In this study, we have identified a novel link between PPARg activation and FKN signaling. On one hand, the activation of PPARg by rosiglitazone in macrophages not only represses the transcription of the FR gene, but also prevents the plasma membrane translocation of the FR protein. On the other hand, the activation of PPARg by rosiglitazone in endothelial cells also impedes the nuclear export of FKN. Together, these data suggest that PPARg activation represses FKN signaling. These findings indicate a previously unrecognized mechanism that may contribute to the anti-inflammatory effect of PPARg.
Introduction
The migration of leukocytes into inflamed peripheral tissues and lymphoid organs involves a cascade of molecular events finely regulated by chemokines and cell adhesion molecules. Fractalkine (FKN), also known as CX3CL1, is a structurally unique chemokine that can act either as a soluble chemotactic factor or as a membrane-anchored adhesion molecule for circulating leukocytes. It is expressed on endothelial cells, smooth muscle cells, and neurons that are activated by proinflammatory cytokines. The FKN receptor (FR), also known as CX3CR1, is expressed on monocytes and mature macrophages, natural killer cells, cytotoxic effector T cells, and mucosal dendritic cells, all of which play important roles in the inflammatory and immune responses.
Accumulating evidence in both clinical studies and animal disease models has shown that FKN signaling is also involved in the pathogenesis of various chronic inflammatory diseases, such as atherosclerosis (Lesnik et al. 2003) , age-related macular degeneration (AMD; Combadiere et al. 2007) , and rheumatoid arthritis (Nanki et al. 2004) . Abrogation of FKN signaling by FR deletion in mice results in reduced accumulation of tissue-specific macrophages, such as foam cells at atherogenic lesions and microglial cells at sites of retinal degeneration. In addition, polymorphisms in human FR, which reduce its binding activity to FKN, have been reported to increase the risk of AIDS and to reduce the risk of coronary artery disease (Faure et al. 2000 , Moatti et al. 2001 . Therefore, the FKN signaling represents a new target for the treatment of an array of inflammatory and immune disorders.
Peroxisome proliferator-activated receptor g (PPARg) is a member of the nuclear hormone receptor superfamily of ligand-responsive transcription factors (Evans et al. 2004) . It forms a functional heterodimer with the retinoid receptor (RXR)a. Certain lipophilic compounds have been identified as PPARg ligands that can bind to the receptor complex and stimulate its transcriptional activity. Naturally occurring PPARg ligands include native and oxidized polyunsaturated fatty acids and arachidonic acid derivatives such as prostaglandins and eicosanoids. Synthetic PPARg ligands include thiazolidinediones (TZDs) such as rosiglitazone (BRL; Willson & Wahli 1997) . PPARg regulates a diverse array of physiological processes including adipogenesis, lipid metabolism, and insulin sensitivity, as well as diseases such as obesity, diabetes, and atherosclerosis. The importance of this receptor is accentuated by the widespread use of TZDs as drugs for insulin resistance and type II diabetes.
Numerous studies using mouse genetic models or synthetic PPARg agonists have suggested that PPARg also regulates both native and acquired immune responses (Bensinger & Tontonoz 2008) . For example, we have recently reported an unexpected yet important role of PPARg in suppressing the production of inflammatory milk lipids in the lactating mammary glands, using a mouse model in which PPARg is specifically deleted in the hematopoietic and endothelial cells. The ingestion of this 'toxic' milk by nursing neonates results in growth retardation and inflammatory alopecia (Wan et al. 2007) . Furthermore, conditional deletion of PPARg in macrophages and intestinal epithelial cells demonstrated that it is important in the regulation of inflammatory bowel disease (Adachi et al. 2006 , Shah et al. 2007 . Surprisingly, macrophage-specific deletion of PPARg was shown to regulate diet-induced obesity and insulin sensitivity, which are the key components of type II diabetes and metabolic syndrome (Odegaard et al. 2007) .
To further understand how PPARg regulates the immune system, we have found that PPARg activation by rosiglitazone suppresses the FKN signaling via multiple mechanisms. In macrophages, rosiglitazone suppresses both the expression and the membrane translocation of FR. In endothelial cells, rosiglitazone prevents the nuclear export of FKN. Taken together, this evidence provides a previously unrecognized mechanism that may contribute to the anti-inflammatory effect of PPARg.
Materials and methods

Macrophage cell culture
For bone marrow-derived macrophages (BMDMs), mouse bone marrow was flushed from the femur and tibia with serum-free DMEM (Invitrogen). After passing through a 40 mm cell strainer, the cells were cultured in macrophage differentiation medium (DMEM containing 20% fetal bovine serum (FBS) and 30% L929 cell-conditioned medium) for 8 days. Differentiated macrophages were replated in RPMI medium containing 10% FBS for various experiments. Peritoneal macrophages were isolated 3 days after thioglycollate challenge and were cultured in RPMI medium containing 10% FBS. The human monocyte cell line THP-1 and the mouse macrophage cell line RAW264.7 were purchased from the American Type Culture Collection (Manassas, VA, USA). Cells were treated with the indicated stimulant in the presence or absence of a ligand before harvesting. BRL was purchased from Cayman Chemical Ann Arbor, Michigan, USA; GW501516 and LG268 were synthesized; TPA (12-0-tetradecanoylphorbol 13-acetate) was obtained from Sigma; and tumor necrosis factor-a (TNFa) was obtained from BD Biosciences (San Jose, CA, USA). Concentrations used were BRL, 1 mM; GW501516, 0 . 1 mM;
LG268, 0 . 1 mM; TPA, 40 ng/ml; and TNFa, 10 ng/ml.
Embryonic stem cell macrophage differentiation
Embryonic stem (ES) cells were trypsinized and depleted of feeder cells by culturing in IMDM (Invitrogen) supplemented with 5% FCS for 3-4 h. Nonadherent ES cells were seeded in 0 . 9% methylcellulose in IMDM supplemented with 15% FCS, transferrin (300 mg/ml, Roche), PFHM-II (5%, Invitrogen), ascorbic acid (50 mg/ml), and monothioglycerol (4!0 K4 M). Embryoid bodies were collected on day 6, trypsinized, and replated in IMDM supplemented with 15% L929 cell-conditioned medium and mIL-3 (1 ng/ml, BD Biosciences Pharmingen). Two days later, macrophage precursors that developed as nonadherent cells were collected and cultured in IMDM supplemented with 15% L929 cell-conditioned medium. Adherent macrophages developed over the next 4 to 5 days, and were used for the experiments starting on day 5 (Keller et al. 1993 , Chawla et al. 2001a .
Transient transfection and reporter analyses
A luciferase reporter was co-transfected into the murine macrophage cell line RAW264.7 cells with expression plasmids for b-gal, PPARg1, and RXRa using Lipofectamine 2000 (Invitrogen). Next day, the cells were treated with 1 mM BRL or DMSO vehicle control for 20-24 h. Luciferase activity was normalized by b-gal. Aox-PPREluc was a positive control. The hFR promoter-luciferase constructs P1, P2, and P3 were generously provided by Dr Combadiere's Laboratory (Garin et al. 2002) . The P2-3 kb-luciferase plasmid was constructed by PCR cloning of the upstream genomic DNA sequence into the pGL3-Basic vector (Promega).
RNA extraction, real-time quantitative PCR and northern blot RNA was extracted using TRIZOL (Invitrogen) according to the manufacturer's protocol. For real-time quantitative PCR (RT-QPCR) analysis, RNA was first treated with RNase-free DNaseI using the DNA-free kit (Ambion, TX, USA) to remove all genomic DNA. Then the RNA was reverse transcribed into the first-strand cDNA using the Superscript First-Strand Synthesis System (Invitrogen). A negative control experiment without reverse transcriptase was performed for all samples to exclude genomic DNA contamination. RT-QPCR (SYBR Green) analyses of the cDNA were performed using an Applied Biosystems 7700 Sequence Detection System. Primer sequences for mouse FR were 5 0 -ATCAGCATC-GACCGGTACCT-3 0 (forward) and 5 0 -GTGACACCGTGCTG-CACTGT-3 0 (reverse). Each reaction was performed in triplicate or quadruplicate in a 384-well format. The expression of each gene was normalized to L19 expression. For the northern blot analysis, total RNA (10 mg) was separated on formaldehyde agarose gel and transferred to Hybond NC nylon membrane (Amersham Pharmacia Biotech). cDNA probes were isolated from IMAGE clones and were labeled with a High Prime kit (Roche) and hybridized with the membrane at 42 8C overnight. After washing, the blot was exposed to a film and quantified by PhosphorImager.
Immunofluorescence staining
The cells were fixed in 2% paraformaldehyde at 4 8C for 30 min, washed, and stained with rabbit anti-hFR or rabbit anti-hFKN primary antibodies (Torrey Pines Biolabs, East Orange, NJ, USA) at 1:200 for 1 h (Hosokawa et al. 2005 , Jamieson et al. 2008 . Following two washes, the cells were stained with FITC-conjugated goat anti-rabbit IgG secondary antibody (Jackson ImmunoResearch Laboratories, West Grove, Pennsylvania, USA) at 1:1000 for 1 h. After two washes, cover slips were mounted with the Vectashield medium containing DAPI (Vector Laboratories Burlingame, CA, USA). Negative control experiments using a nonimmune IgG primary antibody, or a secondary antibody alone without a primary antibody, were performed under the same staining condition to exclude any background signal.
Flow cytometry
Macrophages were cultured in petri dishes and were then detached for fluorescence-activated cell sorting (FACS) analysis with ice-cold PBS containing 5 mM EDTA. All samples were blocked with mouse IgG for 15 min and were then incubated for 15 min at 4 8C with FITC-conjugated antibodies F4/80 (Serotec, Raleigh, NC, USA) or CD11b (Mac-1) (BD Pharmingen, San Diego, CA, USA). Propidium iodide was used for live cell gating. Samples were analyzed on the BectonDickinson FACScan using CellQuest software. A negative control experiment using a FITC-conjugated nonimmune IgG was performed under the same condition to determine the baseline.
Results
Rosiglitazone activation of PPARg down-regulates FR in macrophages
We investigated the effect of PPARg activation by rosiglitazone on cytokine expression in the THP-1 human monocyte cell line and the TPA-differentiated THP-1 macrophages. The RNA expression of FR in TPAdifferentiated THP-1 macrophages was inhibited by BRL in a time-dependent manner ( Fig. 1A and B) . After 24-h treatment, BRL reduced the FR expression by 84%. As a positive control, BRL induced the expression of LXRs by 2 . 2-fold as reported previously (Chawla et al. 2001b) . In contrast, the PPARd agonist GW501516 did not induce LXRs expression, but suppressed FR expression (49%). In addition, the expression of CD44, another cell adhesion receptor for hyaluronic acid, was not significantly affected by BRL or GW501516 treatment. Furthermore, the TPA-induced PPARg expression was also suppressed by 29% after 24-h treatment of BRL, but not by GW501516 treatment. Interestingly, the suppression of FR expression by BRL occurred only in the THP-1 macrophages but not in the THP-1 monocyte precursors in the absence of TPAinduced macrophage differentiation (Fig. 1C) .
We next examined the effect of PPARg activation by BRL on FR expression in primary macrophages that were differentiated ex vivo. First, mouse bone marrow cells were differentiated into macrophages (BMDMs), and treated with BRL, GW501516, LG268 (an RXRa agonist), or vehicle control for 24 h. Both BRL and LG268, but not GW501516, suppressed FR expression (Fig. 1D) . Secondly, mouse peritoneal macrophages were elicited with thioglycollate and were cultured in the presence of each ligand or vehicle control for 24 h. Consistently, FR expression was inhibited by both BRL and LG268, while GW501516 had much less suppressive effect (Fig. 1E) . These results suggested that the activation of the PPARg-RXRa receptor complex by their agonists, BRL and LG268, results in the downregulation of the transcription of the gene encoding the FR in both human and murine macrophages.
Rosiglitazone-activated PPARg suppresses the upstream FR promoter
To test if PPARg directly regulates the promoter for the FR gene, we performed transient transfection and reporter analysis in the murine macrophage cell line RAW264.7 cells. The promoter and upstream genomic DNA region for the human FR gene has been sequenced and characterized (Garin et al. 2002) . Expression vectors for PPARg and RXRa were co-transfected with a luciferase reporter driven by an FR promoter. First, we tested the three proximal promoter regions described by Garin et al. (P1, P2, and P3) . As shown in Fig. 2A , these promoter fragments were not regulated by BRL treatment. To test the upstream promoter region, we cloned a 3 kb genomic DNA fragment into the luciferase reporter construct (P2-3 kb). Luciferase expression from this larger promoter was suppressed by BRL by 47%, suggesting that the PPARg-RXRa receptor complex functions through the upstream FR promoter region to exert the inhibition of its transcription. As a positive control, luciferase expression from the PPRE identified in the acyl-CoA oxidase promoter (Aox-PPRE) was induced by BRL by 8-fold (Fig. 2B) . Primary mouse macrophages were treated with rosiglitazone (BRL, 1 mM), GW501516 (GW, 0 . 1 mM), or LG100268 (LG268, 0 . 1 mM) for 24 h. RNA was isolated and analyzed by RT-QPCR. FR expression was normalized by the expression of the ribosomal protein gene L19. All experiments were repeated at least three times, and representative results are shown. *Indicates P!0 . 05; **indicates P!0 . 01.
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Rosiglitazone suppression of FR expression is PPARg dependent
We next examined whether the inhibitory effect of BRL on FR expression was PPARg dependent or PPARg independent. Since the complete deletion of PPARg in mice results in embryonic lethality (Barak et al. 1999) , we differentiated macrophages from PPARgK/K or wild-type ES cells as described previously ( Fig. 3A ; Chawla et al. 2001a) . As shown in Fig. 3B , ES cells were efficiently differentiated into macrophages, evidenced by the expression of macrophage cell surface markers F4/80 and CD11b by FACS analysis. Both northern blot (Fig. 3C ) and RT-QPCR analyses (Fig. 3D ) demonstrated that BRL inhibited FR expression only in the wild-type macrophages but not in the PPARgK/K macrophages. This indicates that the suppression of FR transcription by BRL is a PPARg-dependent effect, rather than a receptor-independent effect.
Rosiglitazone activation of PPARg disrupts the membrane translocation of FR in macrophages
The function of the FR requires its plasma membrane translocation for ligand binding and signal transduction. We next examined whether BRL activation of PPARg altered the subcellular localization of FR. Immunofluorescent staining using an antibody against the human FR demonstrated that BRL treatment reduced not only the receptor expression but also its membrane association in THP-1 macrophages (Fig. 4) . In the vehicle-treated cells, the majority of the receptors were at the plasma membrane, demonstrated by the bright ring at the cell junctions. In contrast, in the BRL-treated cells, this bright ring was absent, and most of the receptors resided in the cytoplasm and the nucleus. This result suggests that BRL-activated PPARg employs a second mechanism to inhibit FR function in macrophages by hampering its plasma membrane translocation.
Rosiglitazone activation of PPARg prevents FKN nuclear export in endothelial cells
The migration and adhesion of macrophages that express FR also depend on the FKN ligand expressed on the cells in the inflamed tissues, such as endothelial cells. We next examined if BRL treatment regulates the expression and subcellular localization of FKN in the human endothelial cell line HUVEC. First, we measured the RNA expression of FKN using northern blot analysis. FKN was dramatically induced by TNFa by 48-fold, while it was down-regulated by TPA by 76% (Fig. 5A). LG268 treatment for 24 h suppressed the TNFa-induced FKN expression by 30%. In contrast, neither BRL nor GW501516 had an effect on the FKN expression (Fig. 5A) . However, immunofluorescent staining using an antibody against the human FKN demonstrated that BRL treatment did alter its subcellular localization in HUVECs (Fig. 5B) . In the vehicle-treated cells, FKN was concentrated more in the cytoplasm than in the nucleus. In contrast, in the BRL-treated cells, FKN was mainly localized in the nucleus. This result suggests that BRL activation of PPARg may dampen the FKN/FR signaling by impeding FKN nuclear export.
Discussion
In this study, we have identified a novel link between PPARg and the FKN/FR signaling. On one hand, the activation of PPARg by rosiglitazone in macrophages not only represses the transcription of the FR gene, but also prevents the plasma membrane translocation of FR protein. On the other hand, the activation of PPARg by rosiglitazone in endothelial cells also impedes the nuclear export of FKN. Together, these findings indicate a previously unrecognized mechanism that may contribute to the anti-inflammatory effect of PPARg.
We have found that BRL-activated PPARg acts through an upstream promoter region to suppress the transcription of the FR gene in macrophages. A recent study proposed a model for the molecular events that underlie PPARg-mediated transrepression of inflammatory genes in macrophages (Pascual et al. 2005) . Activation of PPARg inhibits inflammatory gene expression by preventing the inflammatory signalspecific removal of the co-repressor complex. In future study, it would be interesting to test whether PPARg regulates the FR promoter via this transrepression mechanism.
Our data have demonstrated that BRL-activated PPARg also prevents FR plasma membrane translocation, which is pivotal for its function as a chemoattractant and adhesion molecule. Human genetic studies identified five SNPs in the FR coding sequence, all of which were in the transmembrane domains of the receptor (Faure et al. 2000) . Two of the mutations (V249I and T280M) were associated with increased susceptibility to HIV infection and accelerated progression to AIDS, as well as reduced risk of acute coronary events, potentially due to a significant decrease in the number of FKN-binding sites per cell (Moatti et al. 2001) . T280M homozygosity was also found to be more frequent in AMD patients, which is likely due to impaired monocyte chemotaxis (Combadiere et al. 2007) . Furthermore, the T280M mutation was independently associated with a lower risk of cardiovascular disease, possibly as the result of reduced cell-cell adhesion under physiological shear conditions (McDermott et al. 2003) . Collectively, these studies demonstrated that the FR transmembrane domain is critical for the FKN-mediated chemotaxis and cell adhesion. Our finding that PPARg activation can disrupt FR membrane association in macrophages Figure 4 Rosiglitazone activation of PPARg disrupts the membrane translocation of FR in macrophages. TPA-differentiated THP-1 macrophages were treated with BRL or DMSO control for 24 h and stained with a rabbit anti-hFR primary antibody followed by a FITC-conjugated goat anti-rabbit IgG secondary antibody. The nuclei were counterstained with DAPI. Negative control experiments were performed using a nonimmune IgG primary antibody, or a secondary antibody alone without a primary antibody, and no background signal was detected (blank images not shown). All experiments were repeated at least three times, and representative results are shown. The cells were treated with BRL or DMSO control for 24 h and stained with a rabbit anti-hFKN primary antibody followed by a FITC-conjugated goat anti-rabbit IgG secondary antibody. The nuclei were counterstained with DAPI. Negative control experiments were performed using a nonimmune IgG primary antibody, or a secondary antibody alone without a primary antibody, and no background signal was detected (blank images not shown). All experiments were repeated at least three times, and representative results are shown.
suggests a secondary but important mechanism by which PPARg inhibits FR function.
We have shown that although BRL-activated PPARg does not affect FKN expression, it does alter FKN subcellular localization. BRL treatment prevents the nuclear export of FKN, resulting in its nuclear accumulation. This suggests that PPARg activation can impede the FKN/FR signaling by an additional mechanism in the endothelial cells where it decreases the membrane association and/or secretion of FKN, thus reducing leukocyte migration and adhesion. In addition, the RXRa agonist LG100268, but not BRL or GW501516, down-regulated the TNFa-induced FKN expression in HUVECs by 30%, suggesting that it may dimerize and activate a nuclear receptor other than PPARg and PPARd to inhibit FKN transcription.
Emerging evidence reveals that PPARg is a key regulator of both lipid metabolism and inflammation. The ability to integrate metabolic signaling and inflammatory signaling makes PPARg an attractive target for intervention in human metabolic diseases and immune disorders. Recent studies demonstrated that the FKN/FR signaling plays an important role in leukocyte migration and adhesion to inflammatory sites, thereby regulating disease processes such as atherosclerosis. Our study revealed a novel link between PPARg activation and FKN/FR signaling, providing a potential mechanism underlying the anti-inflammatory role of PPARg. These findings may enhance our understanding of the effect of the diabetic drug rosiglitazone on diseases including atherosclerosis, type II diabetes, AIDS, and AMD.
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